Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, John Quisel, CEO. Please go ahead. Good morning, and welcome to the ...
Assembly Biosciences, Inc. reported progress in its clinical development of antiviral candidates, with data from multiple programs expected in 2025. Specifically, interim Phase 1b data for long-acting ...
Werewolf Therapeutics updates on clinical trials, financial results, and plans for proprietary T cell engager development amidst strong cash position. Werewolf Therapeutics, Inc. announced significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback